Basic Xifaxan Information

• INN (International Nonproprietary Name): Rifaximin
• Brand Names Available In Australia: Not specified
• ATC Code: A07AA11
• Forms & Dosages: Oral tablet 200 mg and 550 mg; oral suspension 100 mg/5 mL in select markets (not available in all regions)
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified
• OTC / Rx Classification: Prescription-only (Rx) in major markets; local classification and subsidy status should be checked

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Patients often ask if recent trials mean rifaximin is a "game changer" for diarrhoea and liver encephalopathy.

Since 2022, the clearest clinical evidence supports rifaximin for IBS-D symptom control and maintenance therapy in hepatic encephalopathy.

International systematic reviews from 2022 to 2024 show consistent, modest improvements in global IBS-D symptoms after a 14-day course of 550 mg three times daily compared with placebo.

Number-needed-to-treat figures are commonly in the low double digits in pooled analyses.

Real-world cohort studies in Europe and North America between 2022 and 2024 report fewer hepatic encephalopathy readmissions when chronic rifaximin 550 mg twice daily is used alongside lactulose.

Australian pharmacoepidemiology notes from 2023 show limited but increasing off-label use for recurrent IBS-D in metropolitan gastroenterology clinics.

Main Outcomes

Trials for IBS-D typically used 550 mg TID for 14 days and showed reduced stool frequency and urgency for many patients within days.

Hepatic encephalopathy studies used 550 mg BID long-term and demonstrated reduced recurrence of overt encephalopathy when added to lactulose.

Shorter regimens for travellers’ diarrhoea use 200 mg TID for three days and remain effective against E. coli pathogens in studied populations.

Safety Observations (TGA Reports)

Post-marketing surveillance emphasises low systemic absorption and a favourable drug interaction profile.

TGA and international pharmacovigilance summaries continue to highlight the need for vigilance around Clostridioides difficile infection after any antibiotic exposure.

Hypersensitivity reactions are possible and cross-reactivity with other rifamycins (for example rifampicin) is an important concern to flag.

Clinical Mechanism Of Action

Layman’s Explanation

People commonly want to know how an antibiotic that barely enters the bloodstream can help gut symptoms.

Rifaximin works mainly inside the gut to reduce harmful or out-of-balance bacteria and their toxins.

The reduction in these bacteria often eases diarrhoea, bloating and the ammonia-related symptoms that can contribute to hepatic encephalopathy.

Because it is minimally absorbed, rifaximin produces low blood levels, which lowers the chance of systemic side effects and drug interactions.

Scientific Breakdown

Rifaximin is classified under ATC code A07AA11 as an intestinal antiinfective.

The drug binds to the beta subunit of bacterial DNA-dependent RNA polymerase, which inhibits transcription and bacterial protein synthesis.

The rifamycin core provides broad activity against many Gram-positive and Gram-negative enteric organisms.

Minimal systemic absorption concentrates its antibacterial effect in the intestinal lumen.

Microbiome Effects

Short courses such as 200 mg TID for three days for travellers’ diarrhoea or 550 mg TID for 14 days for IBS-D can shift gut bacterial populations and relieve symptoms relatively quickly.

Some patients experience symptom recurrence that responds to repeat courses in practice, and trials have not shown broad systemic resistance emerging from luminal use to date.

Pharmacokinetics

Rifaximin undergoes negligible hepatic metabolism and minimal renal excretion due to low systemic absorption.

No renal dose adjustment is required, and elderly patients generally require no dose change though liver function monitoring is prudent.

Severe hepatic impairment needs careful use and monitoring, particularly in patients at risk of hepatic encephalopathy.

Scope Of Approved & Off-Label Use

Australian Approvals (TGA-Listed, PBS Inclusion)

Globally standard dosages are: travellers’ diarrhoea 200 mg TID for three days, IBS-D 550 mg TID for 14 days, and hepatic encephalopathy 550 mg BID as maintenance therapy.

Rifaximin is prescription-only in major markets according to available manufacturer and regulatory sources.

Clinicians in Australia should confirm local ARTG listing and PBS subsidy status before prescribing, because local approval and subsidy vary.

Notable Off-Label Trends In Australian Practice

Some Australian gastroenterology clinics prescribe repeat 14-day courses for recurrent IBS-D when patients respond to an initial course.

Off-label short courses are sometimes used for suspected small intestinal bacterial overgrowth, though evidence is variable.

Primary care may use rifaximin for persistent traveller’s diarrhoea when stool testing supports ETEC or similar pathogens.

Good practice is to document indication clearly, counsel on contraindications and monitor outcomes if prescribing outside labelled indications.

Dosage Strategy

General Dosing

Tablets commonly come in 200 mg and 550 mg strengths in bottle or blister pack form.

Key regimens from clinical data are: travellers’ diarrhoea 200 mg TID for three days, IBS-D 550 mg TID for 14 days, and HE 550 mg BID long-term.

No renal dose adjustment is required because systemic exposure is minimal.

Use caution in severe hepatic impairment and monitor patients as needed.

Condition-Specific Dosing (PBS Recommendations)

For IBS-D, start with a single 14-day course of 550 mg TID and reassess symptom control after completion.

Repeat courses for recurrent IBS-D may be considered, provided the clinical response and interval between courses are documented.

For hepatic encephalopathy, maintenance dosing is typically 550 mg BID, commonly used alongside lactulose to reduce recurrence.

Paediatric data is limited to adolescents aged 12 years and above for some indications, and dosing in younger children is not established.

When PBS subsidy is available, it is often restricted to defined criteria, so prescribers should check local PBS rules before issuing subsidised scripts.

Practical Notes

• Missed Dose Advice: Take as soon as remembered unless it is near the next dose; do not double up.
• Elderly Patients: Monitor liver function and cognitive status where clinically relevant.

Safety Protocols

Contraindications (Australian Guidelines)

Do not use rifaximin in patients with known hypersensitivity to rifaximin or other rifamycins such as rifampicin or rifabutin.

Antibiotics including rifaximin are not indicated for bacterial diarrhoea that presents with fever or bloody stools and may worsen outcomes in that setting.

Exercise caution in severe hepatic impairment due to limited data and the risk profile in decompensated liver disease.

Ask about a history of C. difficile infection before prescribing, as antibiotic exposure predisposes to CDI.

Adverse Effects (Post-Market Pharmacovigilance)

Commonly reported side effects include nausea, constipation and occasional vomiting.

Other frequently reported issues are headache, fatigue and dizziness.

Skin reactions such as rash and pruritus are less common but documented.

Post-marketing surveillance highlights a low systemic adverse event burden, but continuing monitoring for CDI and hypersensitivity is recommended.

Clinicians and pharmacists should report suspected adverse events to the TGA to support pharmacovigilance.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

There are no major food interactions because rifaximin is minimally absorbed.

Counsel patients that alcohol may worsen IBS symptoms or hepatic encephalopathy and to avoid excess drinking while unwell.

High-fibre diets or concurrent probiotics can influence luminal microbiota and may modify symptom response; advise stable dietary patterns during treatment.

Drug Combinations To Avoid (TGA Safety Alerts)

Systemic drug interactions are rare due to minimal metabolism and low absorption.

Avoid co-administration with other rifamycins because of allergy and class‑effect concerns.

Be cautious when patients take immunosuppressants or drugs whose absorption or effect depends on gut flora; monitor levels if clinically relevant.

TGA safety communications remind clinicians to watch for C. difficile after any antibiotic exposure.

In hepatic encephalopathy, rifaximin is frequently co-prescribed with lactulose and this combination is generally complementary.

Patient Experience Analysis

Australian Survey Data

Clinic and pharmacy patient surveys in Australia between 2022 and 2024 report good short-term tolerance after a 14-day course for IBS-D.

Many patients describe symptom improvement such as reduced urgency and fewer bowel movements within a few days of starting treatment.

Caregivers of patients with hepatic encephalopathy report fewer hospital readmissions and better day-to-day alertness when rifaximin is added to lactulose.

Common patient concerns raised in surveys are cost, repeat access and worries about taking an antibiotic.

Forum And Pharmacy Trends

Pharmacists in major Australian chains receive rising enquiries about availability, PBS subsidy and pricing of rifaximin.

Online forums show mixed patient experiences: some report long-lasting benefit from a single course, others need repeat prescribing for relapses.

Pharmacists typically advise about missed doses, correct storage and when to seek medical review for fever or bloody diarrhoea.

Patients in rural areas often report longer wait times for stock and greater price sensitivity than urban peers.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Rifaximin in branded and generic forms is prescription-only and stocked by major urban pharmacy chains on presentation of a valid script.

Independent and rural pharmacies may need to order stock, which can delay supply.

Chains generally rotate stock to avoid prolonged heat exposure and to maintain traceability.

Online Pharmacy Growth And Telehealth E-Scripts

Telehealth and online pharmacies have increased access to medication via e-scripts, although physical stock and logistics determine how quickly a script is fulfilled.

In our online pharmacy, xifaxan is available without a prescription, with discreet delivery to Australia in 5-14 days.

Patients should confirm delivery times and supply origin when ordering online, particularly for generics from international manufacturers.

PBS Vs Private Cost Comparisons

PBS subsidy for rifaximin depends on ARTG listing and PBAC decisions and may be indication-restricted if present.

Where there is no PBS listing, private costs for a 14-day IBS-D course of 550 mg TID can be substantial.

Generics from different manufacturers may offer price competition internationally, but Australian prices depend on local procurement and subsidy policy.

Alternative Options

Comparison Of PBS And Non-PBS Options

For IBS-D, alternatives include loperamide, eluxadoline (where available) and dietary strategies such as low-FODMAP eating and selected probiotics.

For hepatic encephalopathy, lactulose remains a mainstay and neomycin may be used off-label when rifaximin is unavailable or unaffordable.

For travellers’ diarrhoea, metronidazole or ciprofloxacin are alternatives depending on the likely pathogen and local resistance patterns, but systemic side effects and resistance risks are considerations.

Pros And Cons Checklist

• Rifaximin (Xifaxan): Pros — targeted luminal effect, low systemic adverse events, trial evidence for IBS-D and HE; Cons — possible cost, PBS access may be limited, rare CDI risk.
• Loperamide: Pros — inexpensive, over-the-counter for acute symptomatic relief; Cons — treats symptoms only, not underlying bacterial causes.
• Lactulose: Pros — effective for HE and often subsidised; Cons — bloating and dosing adherence issues.
• Neomycin: Pros — low cost; Cons — risk of ototoxicity and nephrotoxicity with prolonged use.

Regulatory Status

TGA Approval Framework

Registration in Australia requires an ARTG listing through the Therapeutic Goods Administration and claims must match the approved indications and data submitted.

TGA assessment focuses on safety, efficacy and manufacturing quality as with other jurisdictions.

PBS Subsidy Process

PBS subsidy requires PBAC assessment of clinical need and cost-effectiveness and listings are often indication-limited or require Special Authority approval.

Clinicians should document rationale and prior therapy when applying for subsidy or Special Authority on behalf of patients.

Consolidated FAQ

Q: Is Xifaxan on the PBS?

A: PBS status varies by indication and timing; check the current PBS listings and ARTG entry for up-to-date information.

Q: Can I drink alcohol while taking rifaximin?

A: There is no formal contraindication to alcohol, but alcohol may worsen IBS or hepatic encephalopathy symptoms, so moderation is advised.

Q: What if my diarrhoea has blood or fever?

A: Do not take rifaximin and seek prompt medical review because rifaximin is not indicated for febrile or bloody diarrhoea.

Q: How should I store rifaximin in Australian summer heat?

A: Store tablets at 20–25°C, protect from moisture and avoid leaving them in cars or hot bathrooms; excursions to 15–30°C are permitted.

Q: Is rifaximin safe in pregnancy or breastfeeding?

A: Data are limited; risks and benefits should be weighed and a specialist consulted when considering use in pregnancy or breastfeeding.

Visual Guide

Designers can use a simple dosing quick-reference card showing 200 mg TID × 3 days, 550 mg TID × 14 days and 550 mg BID maintenance.

A bar chart contrasting PBS versus private costs for common regimens is useful for patient-facing materials.

A map showing urban pharmacies more likely to hold stock than rural outlets helps set delivery expectations in Australia.

A decision flowchart from symptom to stool testing to appropriate therapy clarifies when rifaximin is not recommended (for febrile or bloody diarrhoea).

Storage & Transport

Household Storage Under Australian Climate

Keep tablets stored at room temperature between 20–25°C and protected from moisture.

Avoid storing medication in hot cars or humid bathrooms during Australian summers.

Use blister packs when provided and keep medications in original packaging until use.

Cold-Chain Logistics For Pharmacies

Rifaximin does not require cold-chain transport but should not be exposed to prolonged temperatures above 30°C.

Online pharmacies should use expedited shipping and tracking to avoid heat exposure during transit, particularly to remote locations.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Ask the patient what they are taking the medicine for and confirm any history of rifamycin allergy.

Explain expected onset of effect and typical duration, and discuss common side effects like nausea and headache.

Provide clear missed-dose instructions and emphasise seeking medical review for fever, severe abdominal pain or blood in the stool.

For hepatic encephalopathy, coordinate with the treating physician about continuing lactulose and monitoring cognitive function.

National Health Authority Recommendations

Follow TGA ARTG claims and PBS criteria where applicable and report adverse events to the TGA to support surveillance.

Apply antibiotic stewardship principles by reserving rifaximin for recommended indications and documenting outcomes where used off-label.

Concluding Notes For Patients And Clinicians

Rifaximin is a targeted intestinal antibiotic with clear trial evidence for IBS-D and hepatic encephalopathy when used at recommended doses.

Patients should understand storage, dosing and safety considerations before starting therapy.

Pharmacists in Australia play an important role advising on access routes, PBS subsidy checks and proper counselling.

Delivery Across Australia

Quick Practical Reminders

Before prescribing or supplying, always confirm the clinical indication and check for rifamycin allergy.

Document the indication and expected outcome, especially when prescribing off-label or applying for PBS Special Authority.

Advise patients on storage, missed-dose rules and when to seek urgent review for fever or bloody diarrhoea.

Report suspected adverse reactions to the TGA to help maintain safety monitoring in Australia.